These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
182 related items for PubMed ID: 16133538
1. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia. Herrington JD, Tran HT, Riggs MW. Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538 [Abstract] [Full Text] [Related]
2. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD. Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671 [Abstract] [Full Text] [Related]
3. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. Cancer Chemother Pharmacol; 1998 Jun; 42(4):307-12. PubMed ID: 9744776 [Abstract] [Full Text] [Related]
4. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula. Nagao S, Fujiwara K, Imafuku N, Kagawa R, Kozuka Y, Oda T, Maehata K, Ishikawa H, Koike H, Aotani E, Kohno I. Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943 [Abstract] [Full Text] [Related]
5. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. Donahue A, McCune JS, Faucette S, Gillenwater HH, Kowalski RJ, Socinski MA, Lindley C. Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850 [Abstract] [Full Text] [Related]
6. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin. Holweger K, Lipp HP, Beijnen JH, Bokemeyer C, Hartmann JT. Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060 [Abstract] [Full Text] [Related]
7. Flat dosing of carboplatin is justified in adult patients with normal renal function. Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Clin Cancer Res; 2006 Nov 01; 12(21):6502-8. PubMed ID: 17085665 [Abstract] [Full Text] [Related]
8. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E. Clin Cancer Res; 2009 May 15; 15(10):3633-9. PubMed ID: 19401344 [Abstract] [Full Text] [Related]
9. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. De Jonge ME, Mathôt RA, Van Dam SM, Beijnen JH, Rodenhuis S. Cancer Chemother Pharmacol; 2002 Sep 15; 50(3):251-5. PubMed ID: 12203108 [Abstract] [Full Text] [Related]
10. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Huitema AD, Mathôt RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH. Clin Pharmacol Ther; 2000 Jun 15; 67(6):621-30. PubMed ID: 10872644 [Abstract] [Full Text] [Related]
11. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Ando M, Minami H, Ando Y, Saka H, Sakai S, Yamamoto M, Sasaki Y, Shimokata K, Hasegawa Y. Clin Cancer Res; 2000 Dec 15; 6(12):4733-8. PubMed ID: 11156227 [Abstract] [Full Text] [Related]
12. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. de Lemos ML, Hsieh T, Hamata L, Levin A, Swenerton K, Djurdjev O, Vu T, Hu F, Conklin J, Malfair Taylor SC. Gynecol Oncol; 2006 Dec 15; 103(3):1063-9. PubMed ID: 16875719 [Abstract] [Full Text] [Related]
13. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Shen M, Schilder RJ, Obasaju C, Gallo JM. Cancer Chemother Pharmacol; 2002 Sep 15; 50(3):243-50. PubMed ID: 12203107 [Abstract] [Full Text] [Related]
14. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Warren K, Gervais A, Aikin A, Egorin M, Balis FM. Cancer Chemother Pharmacol; 2004 Sep 15; 54(3):206-12. PubMed ID: 15156345 [Abstract] [Full Text] [Related]
15. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review. Morrow A, Garland C, Yang F, De Luna M, Herrington JD. J Oncol Pharm Pract; 2019 Oct 15; 25(7):1651-1657. PubMed ID: 30336729 [Abstract] [Full Text] [Related]
16. Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose. Shord SS, Bressler LR, Radhakrishnan L, Chen N, Villano JL. Ann Pharmacother; 2009 Feb 15; 43(2):235-41. PubMed ID: 19193580 [Abstract] [Full Text] [Related]
19. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's]. Nakamura T, Onishi Y, Kono T, Maeda T, Wada T, Hatae M. Gan To Kagaku Ryoho; 1997 Mar 15; 24(5):579-83. PubMed ID: 9087291 [Abstract] [Full Text] [Related]
20. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Wright JD, Tian C, Mutch DG, Herzog TJ, Nagao S, Fujiwara K, Powell MA. Gynecol Oncol; 2008 Jun 15; 109(3):353-8. PubMed ID: 18407341 [Abstract] [Full Text] [Related] Page: [Next] [New Search]